SNC
AVDL

Stifel Nicolaus & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

Stifel Nicolaus & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$85.3K Hold
13,000
– – ﹤0.01% 1447
2013
Q2 		$79.8K Buy
+13,000
New +$67.1K ﹤0.01% 1350

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stifel Nicolaus & Co's AVDL Position: Q3 2013 in Review

Stifel Nicolaus & Co held its Avadel Pharmaceuticals (AVDL) position steady in Q3 2013 at 13,000 shares worth $85.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1447.

Stifel Nicolaus & Co first reported a position in AVDL in Q2 2013 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold AVDL as of Q3 2013.

  • Stifel Nicolaus & Co held 13,000 shares of Avadel Pharmaceuticals worth $85.3K as of Q3 2013.
  • Stifel Nicolaus & Co left its Avadel Pharmaceuticals share count unchanged in Q3 2013.
  • Avadel Pharmaceuticals made up ﹤0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #1447 holding.
  • Stifel Nicolaus & Co first reported a position in Avadel Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • 33 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.